Know Cancer

forgot password

A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma

Phase 2
18 Years
Not Enrolling
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma

Inclusion Criteria


Patients with pathologically confirmed NSCLC which is metastatic or recurrent
(non-resectable), who have failed at least one but no more than two prior therapies for
advanced stage disease or have a recurrence within 6 months of completing adjuvant

Lewis-y antigen expression documented by immunohistochemistry for all patients.

Patients must have:

- Bidimensionally or unidimensionally measurable disease on the basis of physical exam
or imaging studies, or

- Evaluable disease: bone metastases defined on bone scan or malignant pleural effusion

Performance status ≤ 2 (ECOG scale) with a life expectancy of at least 3 months

Patients must be at least four weeks from prior treatment (chemotherapy, hormonal therapy,
or definitive radiotherapy)


Prior therapy with TAXOTERE (docetaxel)

Cumulative anthracycline exposure > 300 mg/m2.

More than one primary malignancy with the exception of:

- Non-melanoma skin cancer

- In situ carcinoma of the cervix

- Localized prostate cancer

- Completely resected stage I or II disease with no evidence of recurrent cancer from
which the patient has remained disease free for more than 3 years.

Uncontrolled significant non-malignant disease (e.g. congestive heart failure, bleeding,
renal failure, hepatic failure).

Uncontrolled, symptomatic brain metastasis.

Peripheral neuropathy > grade 2.

Concomitant therapy with other anti-neoplastic agents or experimental agents except for
small volume radiation to a solitary bony metastasis.

Active viral, bacterial or systemic fungal infections including known HIV or Hepatitis B
or C.

Women who are pregnant or breastfeeding

Any serious underlying medical condition, which would impair the ability of the patient to
receive the planned treatment including prior allergic reactions to recombinant human or
murine proteins.

Dementia or altered mental status that would prohibit the understanding and rendering of
informed consent.

Patients with uncontrolled peptic ulcer disease will be excluded.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Andrew Sandler, MD

Investigator Role:

Study Director

Investigator Affiliation:

Seattle Genetics, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

Completion Date:

October 2003

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Madigan Army Medical Center Tacoma, Washington  98431-5048
Florida Cancer Specialists Fort Myers, Florida  33901
UCLA Medical Center Los Angeles, California  90095-7059
Bendheim Cancer Center Greenwich, Connecticut  06830
University of Chicago Chicago, Illinois  60637
Hematology Oncology Associates of the Treasure Coast Port St. Lucie, Florida  34952
Providence Health System Portland, Oregon  97213
Kaiser Permanente Portland, Oregon  97227
Virginia Mason Research Center Seattle, Washington  98101